Dr. Rosevear: Practicing in a pandemic

The benefit in radiographic progression-free survival extended across all subgroups of patients with HRR-deficient metastatic castration-resistant prostate cancer.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

Overall, 86% maintained a response for greater than 6 months.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

“Our observations in this study show that radium-223 can be integrated into the treatment sequence for patients with (metastatic castration-resistant prostate cancer),” said Daniel Y. Song, MD.

A total of 398 patients with mCRPC, unselected for homologous recombination repair gene alterations.were included in the safety cohort.